Influenza
ICD-10 J10.1; J10.8 · ICD-11 1E30

Hospitalized Influenza: What to Do When Initial Antiviral Treatment Has Not Resolved Symptoms

This protocol addresses hospitalized patients with suspected or confirmed influenza who remain severely ill after completing a standard course of first-line antiviral therapy, with fever and influenza symptoms still present.

Clinical Scenario

The patient is admitted to hospital with suspected or confirmed influenza. Per current recommendations, antiviral treatment was initiated as soon as possible following admission.

Why This Protocol Applies — Prior Treatment Did Not Meet Its Goals

The first treatment line — oral or enterically administered oseltamivir — was started promptly. However, the expected clinical endpoints were not achieved within 5 days: the patient has not experienced shortening of fever duration or resolution of influenza illness symptoms. This persistent severe illness after the standard treatment course is the escalation trigger for the present protocol.

Next-Step Approach (Partial Overview)

The next step involves extending antiviral therapy beyond 5 days. The approach includes options that vary by the antiviral agent used and by patient-specific factors — including immune status and clinical severity — with distinct considerations for immunocompromised patients and those who are most severely ill. The complete selection algorithm, agent-specific guidance, and any dosing modifications are detailed in the full protocol.

Treatment goal: Clinical improvement and resolution of fever and influenza symptoms.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciy866

For hospitalized patients with suspected or confirmed influenza, initiation of antiviral treatment with oral or enterically administered oseltamivir is recommended as soon as possible.

Longer daily dosing (oral oseltamivir or intravenous peramivir) can be considered for hospitalized patients with influenza who remain severely ill after 5 days of treatment.

A higher dose of oral or enterically administered oseltamivir has been recommended by some experts for treatment of influenza in immunocompromised patients and in severely ill hospitalized patients.

Longer treatment regimens might be necessary in immunocompromised patients who may have prolonged influenza viral replication.

View source ↗